BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28649848)

  • 1. Mogamulizumab for the treatment of T-cell lymphoma.
    Makita S; Tobinai K
    Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 3. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
    Winsett FT; Lewis DJ; Duvic M
    Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
    Tobinai K; Takahashi T; Akinaga S
    Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
    Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
    Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
    Remer M; Al-Shamkhani A; Glennie M; Johnson P
    Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
    Sakamoto Y; Fujii K; Murase S; Nakano S; Masaki A; Murase T; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Ishida T; Inagaki H
    Int J Hematol; 2019 Oct; 110(4):389-392. PubMed ID: 31468320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
    Antoniu SA
    Curr Opin Mol Ther; 2010 Dec; 12(6):770-9. PubMed ID: 21154168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo.
    Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y
    Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
    Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
    J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
    Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
    Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
    de Lartigue J
    Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia.
    Mohammed TO; Chagan-Yasutan H; Ashino Y; Nakayama W; Takahashi Y; Shimomura T; Fujimoto T; Watanabe Y; Niki T; Suzushima H; Hattori T
    Tohoku J Exp Med; 2017 Mar; 241(3):201-208. PubMed ID: 28321034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
    Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
    Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
    Tawa M; Kopp E; McCann S; Cantrell W
    Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
    Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
    Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.